MedTrace Logo

To Demonstrate the Relative Bioavailability of Atenolol Tablets

NCT00913965 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability of Atenolol tablets.

Conditions

Interventions

DRUG

Atenolol Tablets 100 mg (Cord Laboratories)

DRUG

Atenolol Tablets 100 mg (Stuart Pharmaceutical)

Sponsors & Collaborators

Principal Investigators

  • Rudolph C. Cane, Jr., M.D. · PharmaKinetics Laboratories Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1989-07-31
Primary Completion
1989-08-31
Completion
1989-08-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00913965 on ClinicalTrials.gov